We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01145144
First Posted: June 16, 2010
Last Update Posted: June 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Meir Medical Center
  Purpose
The aim of this study was to evaluate the effect of dehydroepiandrosterone supplementation on in vitro fertilization performance and outcome among poor-responder patient.

Condition Intervention
Ovarian Stimulation Drug: dehydroepiandrosterone crystalline fine powder

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • peak estradiol level.
  • number of retrieved oocytes.
  • Embryos that were graded as a top quality (according to the number of cells and percent of fragmentation)
  • number of embryos reserved for transfer.

Secondary Outcome Measures:
  • pregnancy rate.
  • live birth rate.

Study Start Date: January 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DHEA supplementation
DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
Drug: dehydroepiandrosterone crystalline fine powder
No Intervention: only induction of ovulation by same long protocol without DHEA

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • previous poor response to ovarian stimulation in IVF.

Exclusion Criteria:

  • patients over the age of 42
  • patients who received DHEA at any time.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01145144


Locations
Israel
Meir Medical center IVF unit
kfar Saba, Israel
Meir Medical Center
Kfar Sava, Israel
Sponsors and Collaborators
Meir Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Adriam Shulman, IVF Unit Meir Medical Center
ClinicalTrials.gov Identifier: NCT01145144     History of Changes
Other Study ID Numbers: mmc07204-2006ctil
First Submitted: May 3, 2010
First Posted: June 16, 2010
Last Update Posted: June 16, 2010
Last Verified: June 2010

Keywords provided by Meir Medical Center:
Dehydroepiandrosterone
DHEA
IVF outcome
long protocol IVF
poor-responder
recombinant LH
embryo quality
pregnancy rate
live birth rate
poor response to ovarian stimulation

Additional relevant MeSH terms:
Dehydroepiandrosterone
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs